Apellis Soars 140% on $5.6 Billion Biogen Acquisition to Expand Rare Disease Portfolio
Summary
Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash, offering $41 per share plus potential contingent value rights of up to $4 per share tied to global sales milestones for Apellis' eye disorder drug Syfovre. This represents a substantial 140% premium to Apellis' last closing price, causing its shares to more than double in premarket trading. For Apellis, this is a definitive exit with a significant payout for shareholders. For Biogen, this acquisition materially expands its rare disease portfolio, building on recent positive developments such as a new license agreement, positive Phase 2 study results, and an FDA approval for Spinraza, indicating a strategic push for pipeline growth. Investors will now watch for the deal's completion and the successful integration of Apellis' assets, particularly the commercial performance of Syfovre.
At the time of this announcement, APLS was trading at $41.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $16.10 to $30.48. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.